Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 3/20 | 0.72 |
| ▸ | CPA1 | P15085 | 2/20 | 0.72 |
| ▸ | CPB1 | P15086 | 1/20 | 0.72 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.72 |
| ▸ | LTA4H | P09960 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27684783 | 0.89 | CYP1A2 (0.59) | CPA3CPA1CPB1CPB2LTA4H | |
| SCHEMBL7506745 | 0.89 | CYP1A2 (0.59) | CPA3CPA1CPB1CPB2LTA4H | |
| SCHEMBL497369 | 0.88 | CYP1A2 (0.68) | CPA3CPA1CPB1CPB2LTA4H | |
| SCHEMBL28912638 | 0.86 | CYP1A2 (0.65) | CPA3CPA1CPB1CPB2LTA4H | |
| SCHEMBL107422 | 0.86 | CYP1A2 (0.65) | CPA3CPA1CPB1CPB2LTA4H | |
| SCHEMBL29865739 | 0.86 | CYP1A2 (0.65) | CPA3CPA1CPB1CPB2LTA4H | |
| SCHEMBL4724923 | 0.86 | CYP1A2 (0.65) | CPA3CPA1CPB1CPB2LTA4H | |
| SCHEMBL40705 | 0.86 | CYP1A2 (0.65) | CPA3CPA1CPB1CPB2LTA4H | |
| SCHEMBL4451600 | 0.86 | CYP1A2 (0.65) | CPA3CPA1CPB1CPB2LTA4H | |
| SCHEMBL2588080 | 0.86 | CYP1A2 (0.65) | CPA3CPA1CPB1CPB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| CN-106831389-B | Method for producing carboxylic acid compound | 中国科学技术大学 | 2020-03-31 | — | — | CN | disclosed |
| US-20180135393-A1 | Methods For Microbially Enhanced Recovery of Hydrocarbons | UTI LP (CA) | 2018-05-17 | — | — | US | disclosed |
| US-4329495-A | USEFUL AS ANALGESICS OR ANTICONVULSANTS, CHIRAL 2-(2-BENZYL-3-MERCAPTOPROPIONYLAMINO)-THIOBUTYRIC ACIDS, OR ALKANOL DERIVATIVES | PFIZER INC. (US) | 1982-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | CPA3 162/4885CPA1 173/4885CPB1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.